Buy & Sell Palo Alto Networks Inc (PANW) – Palo Alto Networks Inc Price Today
Aura AI Summary
Key Stats
- $228.45BMarket Cap
- TechnologySector
- -13.39%3M Drawdown
- $224.29BEnterprise Value
- -Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 86 daysTypical Hold Time
Palo Alto Networks Inc (PANW) is currently valued at a market capitalization of $228.45B, with an enterprise value of $224.29B. Over the past 52 weeks, Palo Alto Networks Inc has traded between a low of $141.67 and a high of $281.69, highlighting its annual price range. Over the past three months, Palo Alto Networks Inc has recorded a drawdown of -13.39%, reflecting recent price volatility. On average, investors hold Palo Alto Networks Inc for approximately 86 days, indicating typical investor behavior on the platform.
About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Most Recent News
ExxonMobil warns oil prices could spike to $160/barrel amid low inventories and geopolitical tensions.
ExxonMobil's Senior Vice President Neil Chapman warned that crude oil prices could surge to $150-$160 per barrel soon due to critically low inventory levels, despite recent price drops linked to U.S.-Iran peace talks. The company highlighted that str...

XRP shows signs of bottoming as smart money accumulates and ETFs hit best month of 2026.
XRP has shown signs of bottoming after a five-month consolidation, with smart money investors increasing accumulation. XRP ETFs recorded their best month in 2026, adding $131 million in inflows in May, contrasting with declines in Bitcoin and Ethereu...

Whitehawk reveals SEZ6 as a promising target for new cancer drug HWK-206, advancing to clinical trials in 2026.
Whitehawk Therapeutics announced data showing SEZ6 protein is highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors, exceeding other known targets. This supports their development of HWK-206, a next-generation antibody dru...
